These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11026015)

  • 1. [Pure antiestrogen for treatment of advanced breast cancers].
    Nomura Y
    Nihon Rinsho; 2000 Apr; 58 Suppl():334-9. PubMed ID: 11026015
    [No Abstract]   [Full Text] [Related]  

  • 2. Fulvestrant (Faslodex): current status in the therapy of breast cancer.
    Bundred N; Howell A
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):151-60. PubMed ID: 12113237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antiestrogen shows promise in ER-positive breast cancers.
    Oncology (Williston Park); 1994 Aug; 8(8):58. PubMed ID: 7947003
    [No Abstract]   [Full Text] [Related]  

  • 4. NFκB signaling is important for growth of antiestrogen resistant breast cancer cells.
    Yde CW; Emdal KB; Guerra B; Lykkesfeldt AE
    Breast Cancer Res Treat; 2012 Aug; 135(1):67-78. PubMed ID: 22527100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.
    Robertson JF
    Br J Cancer; 2001 Nov; 85 Suppl 2(Suppl 2):11-4. PubMed ID: 11900210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fulvestrant antiestrogen for treatment of breast cancer.
    Hancock CM
    Clin J Oncol Nurs; 2003; 7(2):201-2. PubMed ID: 12696217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fulvestrant: a unique antiendocrine agent for estrogen-sensitive breast cancer.
    Kabos P; Borges VF
    Expert Opin Pharmacother; 2010 Apr; 11(5):807-16. PubMed ID: 20151846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in endocrine therapy of metastatic breast cancer.
    Gradishar WJ; Morrow M
    Br J Surg; 2002 Dec; 89(12):1489-92. PubMed ID: 12445055
    [No Abstract]   [Full Text] [Related]  

  • 11. The future of fulvestrant ("Faslodex").
    Howell A
    Cancer Treat Rev; 2005; 31 Suppl 2():S26-33. PubMed ID: 16198056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combining fulvestrant (Faslodex) with continued oestrogen suppression in endocrine-sensitive advanced breast cancer: the SoFEA trial.
    Dodwell D; Coombes G; Bliss JM; Kilburn LS; Johnston S;
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):321-4. PubMed ID: 18387790
    [No Abstract]   [Full Text] [Related]  

  • 13. [Treatment of drug-resistant metastasizing cancer of the breast with an antiestrogen].
    Frederiksen PL; Engelholm A; Mouridsen HT
    Ugeskr Laeger; 1978 Oct; 140(43):2639-41. PubMed ID: 360540
    [No Abstract]   [Full Text] [Related]  

  • 14. Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum Her-2/neu levels: question of tamoxifen resistance.
    Altundag K; Altundag O
    J Clin Oncol; 2003 Dec; 21(24):4656; author reply 4657. PubMed ID: 14673060
    [No Abstract]   [Full Text] [Related]  

  • 15. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A; Robertson J
    Lancet; 1995 Apr; 345(8955):989-90. PubMed ID: 7772169
    [No Abstract]   [Full Text] [Related]  

  • 16. Carboplatin treatment of antiestrogen-resistant breast cancer cells.
    Larsen MS; Yde CW; Christensen IJ; Lykkesfeldt AE
    Int J Oncol; 2012 Nov; 41(5):1863-70. PubMed ID: 22961366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical development of fulvestrant ("Faslodex").
    Howell A; Abram P
    Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice.
    Dauvois S; Geng CS; Lévesque C; Mérand Y; Labrie F
    Cancer Res; 1991 Jun; 51(12):3131-5. PubMed ID: 2039992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to specific anti-oestrogen (ICI182780) in tamoxifen-resistant breast cancer.
    Dowsett M; Johnston SR; Iveson TJ; Smith IE
    Lancet; 1995 Feb; 345(8948):525. PubMed ID: 7861903
    [No Abstract]   [Full Text] [Related]  

  • 20. Differences in morphology and cytoskeleton of MCF-7 and MX-1 cells after therapy with OH-tamoxifen and the pure estrogen antagonist ZM 182780. An immunofluorescence and scanning electron microscopic study.
    Ehlers EM; Schubert C
    Ann Anat; 1999 May; 181(3):231-6. PubMed ID: 10363104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.